In this February 2026 edition of Drugs.com Monthly Update Podcast, learn about new options in weight management, type 2 diabetes, and lung cancer. Discover Eli Lilly's Zepbound KwikPen for simplified dosing in obesity management, the upcoming launch of the oral Ozempic pill for diabetes by Novo Nordisk, IBSA Pharma’s oral film formulation of sildenafil for erectile dysfunction called Vybrique, and the monthly Rybrevant Faspro injection for advanced NSCLC.

• Zepbound KwikPen (tirzepatide): A new multidose Zepbound pen supplying 4 fixed weekly doses in one pen
• Ozempic pill (semaglutide): Discover the upcoming once-daily oral option for adults with type 2 diabetes to manage blood sugar and cardiovascular risks.
• Rybrevant Faspro (amivantamab and hyaluronidase-lpuj): Explore the benefits of a simplified, monthly injectable regimen for EGFR-mutated NSCLC.
• Dupixent (dupilumab): The first approved therapy for allergic fungal rhinosinusitis, reducing the need for systemic steroids.
• Vybrique (sildenafil): A new oral film formulation of sildenafil for erectile dysfunction.
• Calquence + Venetoclax (acalabrutinib combination): This new all-oral regimen provides a targeted therapy for CLL, improving patient outcomes with a non-chemo approach.

Chapters:

• (00:00) - Intro
• (00:20) - Overview

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app